Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients

A population-based cohort study in Taiwan

C. S. Hsu, J. H. Kao, Y. C. Chao, H. H. Lin, Y. C. Fan, C. J. Huang, P. S. Tsai

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background Hepatitis C virus (HCV) infection has been linked to an increased risk of insulin resistance and carotid atherosclerosis. Aim To investigate the association between HCV infection and stroke, and the effect of interferon-based therapy (IBT) on stroke risk in chronic hepatitis C (CHC) patients. Methods We conducted a retrospective cohort study that followed up 3113 subjects with a newly detected HCV infection and 12 452 age- and gender-matched subjects without HCV infection selected from a random sample of 106 beneficiaries from the Taiwan National Health Insurance Program up to 5 years. Use of IBT was defined as treatment with interferon alpha, pegylated interferon alpha-2a or pegylated interferon alpha-2b for at least 3 months. The hazard ratio (HR) for newly detected stroke was calculated for subjects with HCV compared to those without HCV, and for IBT-treated HCV patients compared to non-IBT-treated HCV patients while adjusting for possible confounding factors. Results The overall person-years of follow-up were 8624.11 in patients with HCV, 54 533.69 in patients without HCV, 666.65 in IBT-treated patients, and 7886.49 in nontreated patients. The multivariable-adjusted hazard ratio (HR) for newly detected stroke was 1.23 for subjects with HCV compared to the age- and sex-matched subjects without HCV (adjusted HR = 1.23, 95% CI = 1.06-1.42, P = 0.008). Moreover, use of IBT significantly reduced the risk of stroke in HCV patients (adjusted HR = 0.39, 95% CI = 0.16-0.95, P = 0.039) after adjusting for known prognostic factors. Conclusions Interferon-based therapy may reduce the long-term risk of stroke in patients with chronic HCV infection.

Original languageEnglish
Pages (from-to)415-423
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Chronic Hepatitis C
Taiwan
Hepacivirus
Interferons
Cohort Studies
Stroke
Population
Virus Diseases
Therapeutics
National Health Programs
Interferon-alpha
Carotid Artery Diseases
Insulin Resistance
Retrospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients : A population-based cohort study in Taiwan. / Hsu, C. S.; Kao, J. H.; Chao, Y. C.; Lin, H. H.; Fan, Y. C.; Huang, C. J.; Tsai, P. S.

In: Alimentary Pharmacology and Therapeutics, Vol. 38, No. 4, 08.2013, p. 415-423.

Research output: Contribution to journalArticle

@article{7ca7ef1f901745f3adbe259ee776b9cd,
title = "Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: A population-based cohort study in Taiwan",
abstract = "Background Hepatitis C virus (HCV) infection has been linked to an increased risk of insulin resistance and carotid atherosclerosis. Aim To investigate the association between HCV infection and stroke, and the effect of interferon-based therapy (IBT) on stroke risk in chronic hepatitis C (CHC) patients. Methods We conducted a retrospective cohort study that followed up 3113 subjects with a newly detected HCV infection and 12 452 age- and gender-matched subjects without HCV infection selected from a random sample of 106 beneficiaries from the Taiwan National Health Insurance Program up to 5 years. Use of IBT was defined as treatment with interferon alpha, pegylated interferon alpha-2a or pegylated interferon alpha-2b for at least 3 months. The hazard ratio (HR) for newly detected stroke was calculated for subjects with HCV compared to those without HCV, and for IBT-treated HCV patients compared to non-IBT-treated HCV patients while adjusting for possible confounding factors. Results The overall person-years of follow-up were 8624.11 in patients with HCV, 54 533.69 in patients without HCV, 666.65 in IBT-treated patients, and 7886.49 in nontreated patients. The multivariable-adjusted hazard ratio (HR) for newly detected stroke was 1.23 for subjects with HCV compared to the age- and sex-matched subjects without HCV (adjusted HR = 1.23, 95{\%} CI = 1.06-1.42, P = 0.008). Moreover, use of IBT significantly reduced the risk of stroke in HCV patients (adjusted HR = 0.39, 95{\%} CI = 0.16-0.95, P = 0.039) after adjusting for known prognostic factors. Conclusions Interferon-based therapy may reduce the long-term risk of stroke in patients with chronic HCV infection.",
author = "Hsu, {C. S.} and Kao, {J. H.} and Chao, {Y. C.} and Lin, {H. H.} and Fan, {Y. C.} and Huang, {C. J.} and Tsai, {P. S.}",
year = "2013",
month = "8",
doi = "10.1111/apt.12391",
language = "English",
volume = "38",
pages = "415--423",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients

T2 - A population-based cohort study in Taiwan

AU - Hsu, C. S.

AU - Kao, J. H.

AU - Chao, Y. C.

AU - Lin, H. H.

AU - Fan, Y. C.

AU - Huang, C. J.

AU - Tsai, P. S.

PY - 2013/8

Y1 - 2013/8

N2 - Background Hepatitis C virus (HCV) infection has been linked to an increased risk of insulin resistance and carotid atherosclerosis. Aim To investigate the association between HCV infection and stroke, and the effect of interferon-based therapy (IBT) on stroke risk in chronic hepatitis C (CHC) patients. Methods We conducted a retrospective cohort study that followed up 3113 subjects with a newly detected HCV infection and 12 452 age- and gender-matched subjects without HCV infection selected from a random sample of 106 beneficiaries from the Taiwan National Health Insurance Program up to 5 years. Use of IBT was defined as treatment with interferon alpha, pegylated interferon alpha-2a or pegylated interferon alpha-2b for at least 3 months. The hazard ratio (HR) for newly detected stroke was calculated for subjects with HCV compared to those without HCV, and for IBT-treated HCV patients compared to non-IBT-treated HCV patients while adjusting for possible confounding factors. Results The overall person-years of follow-up were 8624.11 in patients with HCV, 54 533.69 in patients without HCV, 666.65 in IBT-treated patients, and 7886.49 in nontreated patients. The multivariable-adjusted hazard ratio (HR) for newly detected stroke was 1.23 for subjects with HCV compared to the age- and sex-matched subjects without HCV (adjusted HR = 1.23, 95% CI = 1.06-1.42, P = 0.008). Moreover, use of IBT significantly reduced the risk of stroke in HCV patients (adjusted HR = 0.39, 95% CI = 0.16-0.95, P = 0.039) after adjusting for known prognostic factors. Conclusions Interferon-based therapy may reduce the long-term risk of stroke in patients with chronic HCV infection.

AB - Background Hepatitis C virus (HCV) infection has been linked to an increased risk of insulin resistance and carotid atherosclerosis. Aim To investigate the association between HCV infection and stroke, and the effect of interferon-based therapy (IBT) on stroke risk in chronic hepatitis C (CHC) patients. Methods We conducted a retrospective cohort study that followed up 3113 subjects with a newly detected HCV infection and 12 452 age- and gender-matched subjects without HCV infection selected from a random sample of 106 beneficiaries from the Taiwan National Health Insurance Program up to 5 years. Use of IBT was defined as treatment with interferon alpha, pegylated interferon alpha-2a or pegylated interferon alpha-2b for at least 3 months. The hazard ratio (HR) for newly detected stroke was calculated for subjects with HCV compared to those without HCV, and for IBT-treated HCV patients compared to non-IBT-treated HCV patients while adjusting for possible confounding factors. Results The overall person-years of follow-up were 8624.11 in patients with HCV, 54 533.69 in patients without HCV, 666.65 in IBT-treated patients, and 7886.49 in nontreated patients. The multivariable-adjusted hazard ratio (HR) for newly detected stroke was 1.23 for subjects with HCV compared to the age- and sex-matched subjects without HCV (adjusted HR = 1.23, 95% CI = 1.06-1.42, P = 0.008). Moreover, use of IBT significantly reduced the risk of stroke in HCV patients (adjusted HR = 0.39, 95% CI = 0.16-0.95, P = 0.039) after adjusting for known prognostic factors. Conclusions Interferon-based therapy may reduce the long-term risk of stroke in patients with chronic HCV infection.

UR - http://www.scopus.com/inward/record.url?scp=84880296165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880296165&partnerID=8YFLogxK

U2 - 10.1111/apt.12391

DO - 10.1111/apt.12391

M3 - Article

VL - 38

SP - 415

EP - 423

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -